U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H20F4N2O2
Molecular Weight 408.3893
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TARAFENACIN

SMILES

FC1=CC(=CC=C1)N(CC2=CC(F)=C(F)C(F)=C2)C(=O)O[C@H]3CN4CCC3CC4

InChI

InChIKey=UXZDMXYRRQJIBJ-IBGZPJMESA-N
InChI=1S/C21H20F4N2O2/c22-15-2-1-3-16(10-15)27(11-13-8-17(23)20(25)18(24)9-13)21(28)29-19-12-26-6-4-14(19)5-7-26/h1-3,8-10,14,19H,4-7,11-12H2/t19-/m0/s1

HIDE SMILES / InChI

Molecular Formula C21H20F4N2O2
Molecular Weight 408.3893
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Tarafenacin (also known as SVT-40776) was developed as muscarinic M3 receptor antagonist for the treatment of overactive bladder. The drug participated in phase II clinical trial in patients suffering from overactive bladder, where both dose levels of tarafenacin were well tolerated. However, information about the further development of tarafenacin is not available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.5 nM [IC50]
PubMed

PubMed

TitleDatePubMed
Microscopic binding of M5 muscarinic acetylcholine receptor with antagonists by homology modeling, molecular docking, and molecular dynamics simulation.
2012 Jan 12
Phase II drugs that target cholinergic receptors for the treatment of overactive bladder.
2014 Oct
The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study.
2015 Feb
Current and future pharmacotherapy for treating overactive bladder.
2016 Jul
Patents

Sample Use Guides

Tarafenacin 0.2 mg and Tarafenacin 0.4 mg
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Thu Jul 06 21:20:58 UTC 2023
Edited
by admin
on Thu Jul 06 21:20:58 UTC 2023
Record UNII
LDV98UN52Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TARAFENACIN
INN   WHO-DD  
INN  
Official Name English
tarafenacin [INN]
Common Name English
(3R)-1-AZABICYCLO(2.2.2)OCTAN-3-YL (3-FLUOROPHENYL)((3,4,5-TRIFLUOROPHENYL)METHYL)CARBAMATE
Systematic Name English
Tarafenacin [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29704
Created by admin on Thu Jul 06 21:20:59 UTC 2023 , Edited by admin on Thu Jul 06 21:20:59 UTC 2023
Code System Code Type Description
PUBCHEM
25147683
Created by admin on Thu Jul 06 21:20:59 UTC 2023 , Edited by admin on Thu Jul 06 21:20:59 UTC 2023
PRIMARY
EPA CompTox
DTXSID301319099
Created by admin on Thu Jul 06 21:20:59 UTC 2023 , Edited by admin on Thu Jul 06 21:20:59 UTC 2023
PRIMARY
ChEMBL
CHEMBL1779046
Created by admin on Thu Jul 06 21:20:59 UTC 2023 , Edited by admin on Thu Jul 06 21:20:59 UTC 2023
PRIMARY
NCI_THESAURUS
C87644
Created by admin on Thu Jul 06 21:20:59 UTC 2023 , Edited by admin on Thu Jul 06 21:20:59 UTC 2023
PRIMARY
SMS_ID
300000037038
Created by admin on Thu Jul 06 21:20:59 UTC 2023 , Edited by admin on Thu Jul 06 21:20:59 UTC 2023
PRIMARY
FDA UNII
LDV98UN52Y
Created by admin on Thu Jul 06 21:20:59 UTC 2023 , Edited by admin on Thu Jul 06 21:20:59 UTC 2023
PRIMARY
CAS
385367-47-5
Created by admin on Thu Jul 06 21:20:59 UTC 2023 , Edited by admin on Thu Jul 06 21:20:59 UTC 2023
PRIMARY
INN
9065
Created by admin on Thu Jul 06 21:20:59 UTC 2023 , Edited by admin on Thu Jul 06 21:20:59 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY